breakthrough! The new anti-cancer drug can 'kill' a variety of cancers, and it has been tested in China, and the effect of cancer treatment is remarkable

The development of human medicine is changing with each passing day. Have you ever been amazed by any achievement?

For many years, human beings have been fighting against cancer, taking more and more initiative in every bit of medical progress. Now, more and more anticancer drugs are on the market, bringing hope to cancer patients. In 2018, the anticancer drug Vitrakvi was launched in the United States, attracting attention from all over the world.

Vitrakvi has two identities. It is not only the first oral TRK inhibitor officially approved for marketing, but also the first " broad-spectrum anticancer drug " independent of tumor type.

" Even anti-cancer drugs have broad-spectrum ? " Hearing this news, many people will ask such questions.

As one of the major diseases that threaten human health and life, cancer has always been a shadow in many people's hearts. But if there is a special drug that can control cancer and make cancer like chronic diseases such as high blood pressure and diabetes, it will be considered a blessing in misfortune.

Therefore, it is not difficult to understand why the medical community is so excited about the launch of broad-spectrum anticancer drugs.

1. New anticancer drugs are approved

In June of this year, the good news came again. The Center for Drug Evaluation (CDE) of the State Drug Administration of China issued an announcement granting Ribotinib two breakthrough treatment designations .

Ribotinib, known as Repotrectinib in English and code -named TPX-0005, is a new generation of oral targeted drugs targeting multiple targets of ALK, ROS1 and NTRK . According to the published test data, Ribotinib has performed well and has relatively great potential.

In May this year, the U.S. FDA granted Ribotinib the Breakthrough Therapy Designation. At present, Ribotinib has obtained seven FDA special approval channel certifications.

2. The domestic test results are released, and the effect is gratifying

Why is Ribotinib so highly recognized? What is so great about it?

At last year's World Conference on Lung Cancer, Ribotinib made a stunning debut and caused a sensation. The data shows that in the phase I/II study of TRIDENT-1, the objective response rate of ribotinib for ROS1-positive patients with specific mutations reached 93% , breaking the previous record and being highly expected by the medical community.

In addition, at the 53rd International Society of Pediatric Oncology (SIOP), Harvard Medical School announced the Phase 1/2 clinical data of Ribotinib, and the results showed that Ribotinib was well tolerated in children with tumors. Three of the four tyrosine kinase inhibitor (TKI)-naïve patients had a definite response, and one patient had complete remission with all tumor lesions disappearing .

Recently, the domestic trial results of Ribotinib were also announced. Data Display:

In the initial treatment group, the overall response rate of 11 Chinese patients reached 91%;

In the second-line group, the overall response rate of 11 Chinese patients was 36%;

In the back-line group, the overall response rate of 4 Chinese patients was 50%;

In the targeted drug resistance group, the overall response rate of the 3 Chinese patients was 67%;

Preliminary efficacy analyzes of ribotinib are very encouraging and may play a larger role in the future.

3. Outstanding advantages, clinical trials will continue

At present, the clinical trials of Ribotinib in China are still in progress and recruiting, mainly targeting non-small cell lung cancer solid tumors carrying rearrangements of ROS1, NTRK1, NTRK2 and NTRK3.

What are the specific advantages of Ribotinib, which is expected to become the best drug candidate of its kind in patients with ROS1-positive advanced NSCLC?

First of all , Ribotinib is a specially designed low-molecular-weight macrocyclic TKI with "broad-spectrum" and can be used to treat ROS1, TRKA-C and ALK target-positive lung cancer, colon cancer, melanoma, thyroid cancer, gastrointestinal Solid tumors such as stromal tumors and cholangiocarcinoma.

Secondly , clinical data show that Ribotinib has better anti-cancer performance than other drugs with the same target.

More importantly , Ribotinib can overcome the currently known drug resistance problems of ALK, ROS1 and NTRK. Although the current targeted drugs can significantly prolong the survival of patients, the problem of drug resistance has inevitably emerged, and there is no good solution, and Ribotinib can fill the corresponding gap.

4. When taking targeted drugs, these 3 things should be paid attention to

Targeted drugs bring hope to patients, but patients should pay attention to the following points when taking drugs, so as not to affect the therapeutic effect.

1. Do not increase or decrease the dosage by yourself

Follow the doctor's advice and do not increase or decrease the dosage without authorization. The frequency and dose of targeted drugs are scientifically formulated. Only when taken on time and in the right amount can the best effect be achieved, adverse reactions reduced, and the emergence of drug resistance delayed.

2. Recheck in time if the effect drops

Pay close attention to your physical condition while taking the medicine, because after a period of time, the tumor may become less sensitive to the medicine and the effect will decline. If this happens, you should review in time, choose other targeted drugs under the guidance of a doctor, or change the treatment method.

3. Always pay attention to side effects

Targeted drugs are not a panacea, and side effects such as rash, diarrhea, elevated transaminases, oral mucositis, and oral ulcers may occur. If the symptoms are mild, they can be solved in a targeted manner. But be careful, if the symptoms are severe, stop taking the medicine immediately and seek medical attention.

In fact, being able to take targeted drugs is already a blessing in misfortune. After all, not everyone has a suitable target. Therefore, patients must listen to the doctor's advice when taking medicine, and don't be self-willed, so as not to hurt themselves.

References:

[1] Center for Drug Evaluation, State Drug Administration of China. Information Disclosure. Publicity of Breakthrough Therapy. 2022-06-01

[2] The remission rate of patients with drug-resistant mutations was 59%! Ribotinib Receives Two Breakthrough Therapy Designations for Non-Small Cell Lung Cancer in China. Gene Drug Exchange. 2022-06-20

[3] 10 things you have to know when taking targeted drugs! Once explained clearly, rash, diarrhea, elevated transaminases.... China Medical Tribune Today Tumor. 2022-03-10

Reprinting is prohibited without the author's permission